Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use HYMPAVZI safely and effectively. See full prescribing information for HYMPAVZI. HYMPAVZI (marstacimab-hncq) injection, for subcutaneous useInitial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: •hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or •hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
- generic_name
- marstacimab-hncq
- product_names
- marstacimab-hncq
- ndc
- 0069-2151, 0069-2151-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en